Completed PHASE4 INTERVENTIONAL NCT00266318

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy

Sponsor: Beth Israel Medical Center

Conditions Hepatitis C

Interventions Interferon Alfacon-1 and Ribavirin

Updated 5 times since 2017 Last updated: Apr 16, 2008 Started: Dec 31, 2005 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00266318, this PHASE4 trial focuses on Hepatitis C and remains completed. Sponsored by Beth Israel Medical Center, it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Medical Center
InterMune

Data source: Beth Israel Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States